Trevi Therapeutics Inc (TRVI) outlines a cash runway into 2030, positive FDA feedback for non-IPF ILD, and a clear path to potential first-in-class status in chronic cough indications.
Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Detailed price information for Trevi Therapeutics Inc (TRVI-Q) from The Globe and Mail including charting and trades.
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global He
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
This is the newest page. Registered accounts read further back.